Interim report
Page 1
Email – investorservices@torrentpharma.com 23rd October, 2026 The Dy. General Manager (Listing Dept.) The Manager – Listing Dept., BSE Limited, National Stock Exchange of India Ltd., Corporate Relationship Dept., Exchange Plaza, 5 th Floor, 1st Floor, New Trading Ring, Plot No. C/1, G. Block, P. J. Towers, Dalal Street, Fort, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 (BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM) Dear Sir, Sub.: Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) We would like to inform that the Board has at its meeting held today approved, inter alia, the Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with limited review report of the Company for the quarter and half year ended 30th September, 2026. The said financial results are enclosed herewith as an Annexure A. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter and half year ended on 30 th September, 2026. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com A Press Release on Financial Results which is being submitted to the media is also enclosed herewith as an Annexure B. The Board meeting commenced at 02:00 pm and concluded at 04:00 pm. The above is for your information and record. Thanking you, Yours Sincerely, For TORRENT PHARMACEUTICALS LIMITED CHINTAN M. TRIVEDI COMPANY SECRETARY Encl: A/a TORRENI PHARMA TORRENT PHARMACEUTICALS LIMITED CIN, L24230GJ1972PLC002126 Regd. Office, Avirat, Thaltej Shilaj Road, Ahmedabad - 380059 Phone, +91 79 26599000, Fax, +91 79 26582100, www.torrentpharma.com
Page 2
Annexure A BS R & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing Nesco IT Park 4, Nesco Center Western Express Highway Goregaon (East), Mumbai -400 063, India Telephone +91 (22) 6257 1000 . Fax +91 (22) 6257 1010 lndeoendent Auditor's Reoort To the Board of Directors of Torrent Pharmaceuticals Limited Report on the audit of the Standalone Financial Results Opinion We have audited the accompanying standalone quarterly financial results of Torrent Pharmaceuticals Limited ("the Company") for the quarter ended 30 September 2026 and the year-to-date results for the period from 1 April 2026 to 30 September 2026 (in which are included the standalone financial information of erstwhile J. B. Chemicals & Pharmaceuticals Limited (JBCPL), pursuant to the Scheme of Arrangement in the nature of Amalgamation of JBCPL with the Company which has been approved by the National Company Law Tribunal vide its order dated 06 July 2026 with the appointed date of 21 January 2026), attact1ed herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. In our opinion and to the best of our information and according to the explanations given to us, these standalone financial results: a. are presented in accordance with the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 in this regard; and b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the quarter ended 30 September 2026 as well as for the year to date results for the period from 1 April 2026 to 30 September 2026. Basis for Opinion We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion. Management's and Board of Directors' Responsibilities for the Standalone Financial Results These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Management and the Board of Directors are responsible for the preparation of these standalone financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted <? -!;>-- BS R & Co. (a partnership firm with Registration No. BA61223) converted into BS R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-6181) with effect from October 14, 2013 Registered Office: 14th F(oor, Central B Wng and North C Wing, Nesco IT Pa~ 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai -400063 Page 1 of 3
Page 3
8 SR & Co. LLP Independent Auditor's Report (Continued) Torrent Pharmaceuticals Limited in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error. In preparing the standalone financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern , disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors is also responsible for overseeing the Company's financial reporting process. Auditor's Responsibilities for the Audit of the Standalone Financial Results Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance , but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also: Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors. Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained , whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion . Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern. Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures , and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation . We communicate with those charged with governance regarding, among other matters, the planned scope and ti min of the audit and significant audit findings , including any significant deficiencies in internal control th ......:::=-=::::-,... our audit. Page 2 of 3
Page 4
BS R & Co. LLP Independent Auditor's Report (Continued) Torrent Pharmaceuticals Limited We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. Other Matter The corresponding amounts for the year ended 31 March 2026, includes financial results of JBCPL (considered pursuant to the Scheme of Amalgamation of JBCPL with the Company as stated in Note 5), whose financial results reflect total assets of Rs. 4,823.50 crores as at 31 March 2026, total revenue of Rs. 712.74 crores, total net profit after tax of Rs. 133.97 crores and total comprehensive income of Rs. 136.45 crores, for the period from 21 January 2026 to 31 March 2026. These financial results of JBCPL has been audited by other auditor who had expressed an unmodified opinion. Our opinion is not modified in respect of this matter. Ahmedabad 23 October 2026 For B S R & Co. LLP Chartered Accountants Firm's Registration No.: 101248W/W-100022 Sadashiv Shetty Partner Membership No.: 048648 UDIN:26048648EXELKZ5012 Page 3 of 3
Page 5
TORRENT" PHARMA TORRENT PHARMACEUTICALS LIMITED Registered Office: "Avirat'', Thaltej Shilaj Road, Ahmedabad - 380059, Gujarat, India, Ph.:+ 91 79 26599000 Fax:+ 91 79 26582100 CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com Statement of Standalone Financial Results for the Quarter and Half Year ended September 30, 2026 Quarter ended Half Year ended 30-Sep-2026 30-Jun-2026 30-Sep-2025 30-Sep-2026 30-Sep-2025 Particulars Audited Unaudited Audited Audited Audited 1 Revenue from operations (a) Revenue from contracts with customers 4063 4073 2707 8136 5274 (b) Other operating income 82 85 55 167 104 Total revenue from operations 4145 4158 2762 8303 5378 2 Other income (Refer Note 8) (11) (21) (27) (32) (32) 3 Total income (1 + 2) 4134 4137 2735 8271 5346 4 Expenses (a) Cost of materials consumed 584 609 382 1193 776 (b) Purchases of stock-in-trade 369 277 186 646 359 (c) Changes in inventories of finished goods, work-in-progress 5 52 53 57 70 and stock-in-trade (d) Employee benefits expense 669 677 460 1346 913 (e) Finance costs 287 293 37 580 82 (f) Depreciation and amortisation expense 587 575 189 1162 376 (g) Other expenses 947 970 609 1917 1209 Total expenses 3448 3453 1916 6901 3785 5 Profit before exceptional items and tax (3 - 4) 686 684 819 1370 1561 6 Exceptional items (Refer Note 6) 10 21 13 31 13 7 Profit before tax (5 - 6) 676 663 806 1339 1548 8 Tax expense (a) Current tax 260 266 220 526 418 (b) Deferred tax (82) (95) (11) (177) (18) Total tax expense 178 171 209 349 400 9 Net profit for the period (7 • 8) 498 492 597 990 1148 10 Other comprehensive income (A) (i) Items that will not be reclassified subsequently to (12) (17) (2) (29) (11) profit or loss (ii) Income tax relating to items that will not be 3 4 1 7 3 reclassified subsequently to profit or loss (B) (i) Items that will be reclassified subsequently to profit 18 107 (72) 125 (99) or loss (ii) Income tax relating to items that will be reclassified (4) {27) 18 {31) 25 subsequently to profit or loss Total other comprehensive income 5 67 (55) 72 (82) 11 Total comprehensive income (9 + 10) 503 559 542 1062 1066 12 Paid-up equity share capital (Face value of Rs. 5 each) 190.18 169.23 169.23 190.18 169.23 13 Other equity excluding revaluation reserves 14 Earnings per share (Face value of Rs. 5 each) (not annualised): Basic (in Rs.) 13.09 12.94 17.64 26.03 33.92 Diluted (in Rs.) 13.09 12.94 17.64 26.03 33.92 See accompanying notes to the standalone financial results ( Rs. in crores) Year ended 31-Mar-2026 Audited, Restated (Refer note 5) 11199 223 11422 (70) 11352 1748 832 (47) 1990 342 1057 2620 8542 2810 89 2721 767 (80) 687 2034 (3) 1 (191) 48 (145) 1889 169.23 17407 58.70 58.70
Page 6
TORRENT" PHARMA Notes: 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on October 23, 2026. The statutory auditors have carried out an audit of the above said results. There is no qualification in the auditor's report on this statement of financial results. 2 The Company operates in a single segment i.e. Generic Formulation Business. 3 Standalone Balance Sheet Particulars A ASSETS 1 Non-current assets Property, plant and equipment Capital work-in-progress Investment properties Right-of-use assets Goodwill Other intangible assets Intangible assets under development Financial assets Investments Loans Other financial assets Other tax assets (net) Other non-current assets Total non-current assets 2 Current assets Inventories Financial assets Investments Trade receivables Cash and cash equivalents Bank balances other than cash and cash equivalents Loans Other financial assets Other current assets Total current assets 3 Non-current assets held for sale TOTAL ASSETS (1+2+3) (Rs. in crores) Audited As at 30-Sep-2026 As at 31-Mar-2026 Restated (Refer note S) 4123 3961 400 445 13 13 553 562 3917 3917 23234 24165 22 36 887 855 2 3 20 33 909 891 58 86 28 31 33257 34107 2221 2170 2073 866 3606 3350 82 97 22 48 5 5 220 531 6008 4897 574 538 8803 7605 1 1 42061 41713
Page 7
TORRENT'" PHARMA (Rs. in crores) Audited Particulars As .at As at 30-Sep-2026 31-Mar-2026 Restated (Refer note 5) B EQUITY AND LIABILITIES 1 Equity Equity share capital 190 169 Other equity 18066 17407 Total equity 18256 17576 2 Non-current liabilities Financial liabilities Borrowings 11428 11462 Lease liabilities 92 94 Other financial liabilities 29 86 11549 11642 Provisions 700 579 Deferred tax liabilities (net) 5524 5677 Other non-current liabilities 1 4 Total non-current liabilities 17774 17902 3 Current liabilities Financial liabilities Borrowings 1707 2703 Lease liabilities 22 21 Trade payables Total outstanding dues of micro enterprises and small enterprises 130 163 Total outstanding dues of creditors other than micro enterprises and 1131 1011 small enterprises Other financial liabilities 2147 1890 5137 5788 Other current liabilities 95 97 Provisions 298 280 Current tax liabilities (net) 501 70 Total current liabilities 6031 6235 TOTAL EQUITY AND LIABILITIES (1+2+3j 42061 41713
Page 8
TORRENT'" PHARMA 4 Standalone Statement of Cash Flows {Rs. in crores) Audited Particulars Half Vear ended Half Vear ended 30-Sep-2026 30-Sep-2025 A CASH FLOWS FROM OPERATING ACTIVITIES PROFIT BEFORE TAX 1339 1548 Adjustments for : Depreciation and amortisation expense 1162 376 Allowance for expected credit loss (net)* 6 0 Unrealised foreign exchange loss (net) 29 40 Loss on disposal of property, plant & equipment and other intangible assets 4 1 (including non-current assets held for sale) (net) Gain on sale of current investments (net) (53) (9) Finance costs 580 82 Rent income (2) - Interest income (9) (2) 3056 2036 Movement in working capital : Trade receivables (346) (428) Loans and other assets (10) (126) Inventories (51) 68 Trade payables 87 (7) Liabilities and provisions 63 (91) CASH GENERATED FROM OPERATIONS 2799 1452 Income taxes paid (net of refunds) (69) (365) NET CASH FROM OPERATING ACTIVITIES 2730 1087 B CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property, plant and equipment and other intangible assets (330) (171) (including payment towards capital work-in-progress, intangible assets under development and capital advances) Proceeds from disposal of property, plant & equipment and other intangible 2 1 assets (Including advance received against non current asset held for sale) Payment for investment in subsidiaries (27) (31) (Investments in)/ Redemption of mutual funds (net) (1155) 32 Maturity of/ (Investment in) fixed deposits (net) 303 (68) Income from investment properties 1 - Interest received 27 2 NET CASH USED IN INVESTING ACTIVITIES (1179) (235) C CASH FLOWS FROM FINANCING ACTIVITIES Repayment of long-term borrowings (66) (306) Repayment of short term borrowings (net) (1050) (248) Repayment of lease liabilities (14) (11) Dividend paid (381) (203) Interest and other borrowing cost paid (55) (125) NET CASH USED IN FINANCING ACTIVITIES (1566) (893) NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS (A+B+C) (15) (41) CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD 97 105 Effect of exchange rate changes on foreign currency cash and cash equivalents* 0 - CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 82 64 *Represents value less than Rs. 0.50 crore.
Page 9
TORRENT" PHAR MA 5 On January 21, 2026, the Company acquired controlling stake of 48.80% in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma). The Scheme of Amalgamation of JB Pharma with the Company was approved by the Hon'ble National Company Law Tribunal (NCLT), Ahmedabad Bench, on July 6, 2026. Upon filing the Scheme with Registrar of Companies (ROC), the Scheme became effective on July 8, 2026, with an appointed date of January 21, 2026. Consequently, JB Pharma has been amalgamated with the Company and dissolved without being wound up. On July 20, 2026, the Company allotted 4,19,22,416 fully paid-up equity shares of Rs. 5 each to the eligible shareholders of JB Pharma as on the record date, July 17, 2026, in the share exchange ratio of 51 fully paid up equity shares having face value of Rs. 5 each of the Company for every 100 fully paid up equity shares having face value of Rs. 1 each of JB Pharma. During the quarter ended June 30, 2026, the management had determined the amalgamation to be a subsequent adjusting event and impact of amalgamation had been accounted using the pooling of interest method in accordance with Appendix C to Ind AS 103, Business Combinations, with effect from the appointed date, January 21, 2026, as specified in the approved Scheme. Accordingly, the comparative financial information for the year ended March 31, 2026, had been restated after recognizing the effect of amalgamation as above. The amount of Revenue from operations and profit before tax published in the previous period before recognizing the effect of amalgamation are shown below - (Rs. in crores) Particulars Year ended 31-Mar-2026 Total revenue from operations 10712 Profit Before Tax 2897 The financial results do not include the effect of the stamp duty payable in respect of the Scheme of Amalgamation, pending adjudication by the appropriate authority. 6 Exceptional items (i) Includes litigation settlement of Rs. 10 crores for the quarter and half year ended September 30, 2026. (ii) Includes Rs. 2 crores for the quarter ended June 30, 2026 and half year ended September 30, 2026, Rs. 13 crores for the quarter and half year ended September 30, 2025 and Rs. 70 crores for the year ended March 31, 2026, pertaining to regulatory and statutory fees, along with other related costs associated with JB Pharma's acquisition and merger as mentioned in Note 5 above. (iii) Includes inventory write-off of Rs. 19 crores for the quarter ended June 30, 2026 and half year ended Sep 30, 2026 consequent to fire incident at one of the erstwhile JB Pharma warehouses. No effect has been given to the related insurance claim, which is under assessment. (iv) Includes severance compensation of Rs. 19 crores for the year ended March 31, 2026, incurred on account of restructuring of JB Pharma's distribution network. 7 The listed non-convertible debentures of the company aggregating Rs. 10990 crores as at September 30, 2026 (as at March 31, 2026 : Rs.10990 Crores) are secured by first ranking exclusive charge by way of hypothecation over the designated account assets and the specified trademarks of the company including its future line extensions. The security cover thereof exceeds 110% of the principal amount and interest accrued on the said debentures. The listed non-convertible debentures of the company aggregating Rs. 143 crores as at March 31, 2025 has been fully repaid during the year ended March 31, 2026.
Page 10
TORRENT'" PHARMA 8 Other income mainly includes interest income, dividend income, net gain on sale of investments, net foreign exchange gain/(loss) and net gain/(loss) on disposal of property, plant & equipment and other intangible assets. 9 Refer Annexure I for disclosure required pursuant to Regulation 52(4) and 54(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) . Place : Ahmedabad, Gujarat Date : October 23, 2026 For TORRENT PHARMACEUTICALS LIMITED ""\ h ~r••~ . __ ,,.,,.,,-·~tAN MEHTA Managing Director DIN : 08174906
Page 11
TORRENT PHARMA ANNEXURE I: (Rs. in crores except as stated otherwise) Additional Disclosure as per regulation 52(4) and 54(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Particulars Regulation No. Paid up debt capital Net worth 52(4)(f) Debenture redemption reserve 52(4)(e) Debt equity ratio (in times) 52(4)(a) Debt service coverage ratio (in times) 52(4)(b) Interest service coverage ratio (in times) 52(4)(c) Current ratio (in times) 52(4)(i) Long term debt to working capital (in times) 52(4)(j) Bad debts to Account receivables ratio (in times) 52(4)(k) Current liability ratio (in times) 52(4)(1) Total debts to total assets (in times) 52(4}(m) Debtors turnover (in times) (Annualised} 52(4)(n) Inventory turnover (in times) (Annualised) 52(4)(0) Operating margin (in%) 52(4}(p) Net profit margin (in%} 52(4)(q) Security cover ratio (in times) 54(3) Ratios have been computed as follows:- (a) Debt equity ratio: Total debt/ Net worth Total debt: Non-current borrowings+ current borrowings Net worth: Equity share capital+ Other equity Quarter ended 30-Sep-2026 30-Jun-2026 ·11390 11390 18256 17754 - - 0.72 0.78 3.95 3.88 4.51 4.40 1.46 1.29 3.88 5.55 0.01 0.01 0.25 0.26 0.31 0.33 4.50 4.67 7.42 7.52 37.6% 37.2% 12.0% 11.8% 1.41 1.44 Half Year ended Year ended 31-Mar-2026 30-Sep-2025 30-Sep-2026 30-Sep-2025 (Restated) 643 11390 643 11390 8455 18256 8455 17576 36 - 36 - 0.24 0.72 0.24 0.81 3.19 3.91 4.01 3.27 22.30 4.45 19.52 10.09 1.85 1.46 1.85 1.22 0.48 3.88 0.48 7.29 0.00 0.01 0.00 0.01 0.55 0.25 0.55 0.26 0.15 0.31 0.15 0.34 4.33 4.68 4.39 4.06 7.15 7.41 6.91 6.00 37.8% 37.4% 37.5% 36.8% 21.6% 11.9% 21.3% 17.8% 17.01 1.41 17.01 1.47 (b) Debt service coverage ratio: (Profit after tax+ Deferred tax+ Depreciation and amortisation+ Interest on debt and lease+ Exceptional items)/ (Interest on debt and lease + Principal repayments of long term debt including lease payment) (c) Interest service coverage ratio: (Profit after tax+ Deferred tax+ Depreciation and amortisation+ Interest on debt and lease+ Exceptional items)/ Interest on debt and lease (d} Current Ratio: Total current assets/ Total current liabilities (e) Long term debt to working capital : Non-current borrowings (incl. current maturities of long-term borrowings)/ Net working capital Net Working capital : Total current assets - Current liabilities Current liabilities: Total current liabilities - current maturities of long-term borrowings (f) Bad debts to Account receivables ratio : Allowances for expected credit loss/ Gross trade receivables (g) Current liability ratio: Total current liabilities/ Total liabilities (h) Total debts to total assets: Total borrowing/ Total assets Total borrowing : Non-current borrowings+ current borrowings (i) Debtors turnover: Net sales/ Average trade receivables U) Inventory turnover: Net sales/ Average Inventories (k) Operating margin%: Revenue from operations - (cost of goods sold+ employee benefits+ other expenses)+ (other income - interest income - dividend income)/ Revenue from operations (I) Net profit margin%: Profit after tax/ Revenue from operations (m) Security cover ratio: Total assets available for secured debt securities (secured by either pari-passu or exclusive charge on assets including assets given on first pari passu basis to term loan lenders)/ Total borrowing through issue of secured Debt securities and other borrowings (secured by first pari-passu charge on aforementioned assets) including interest accrued.
Page 12
BS R & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing Nesco IT Park 4, Nesco Center Western Express Highway Goregaon (East), Mumbai - 400 063, India Telephone +91 (22) 6257 1000 Fax +91 (22) 6257 1010 Limited Review Report on unaudited consolidated financial results of Torrent Pharmaceuticals Limited for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended To the Board of Directors of Torrent Pharmaceuticals Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Torrent Pharmaceuticals Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended. 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 , as amended. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable . 4. The Statement includes the results of the entities mentioned in Annexure I to the Statement. 6 SR & Co. (a partnership firm witll Registration No. BA61223) converted in1o 8 SR & Co. LLP (a Limited Liability Partnership with LLP Regis1ration No. AAB-8181) witl1 effect from October 14, 2013 Registered Office: 14l11 F(oor, Central B Wrng and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East}, Mumbai - 400063 Page 1 of 4
Page 13
BS R & Co. LLP Limited Review Report (Continued) Torrent Pharmaceuticals Limited 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021,as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. Ahmedabad 23 October 2026 For B S R & Co. LLP Chartered Accountants Firm's Registration No.:101248W/W-100022 Sadashiv Shetty Partner Membership No.: 048648 U DI N:26048648E BWAIO3702 Page 2 of 4
Page 14
BS R & Co. LLP Limited Review Report (Continued) Torrent Pharmaceuticals Limited Annexure I List of entities included in unaudited consolidated financial results.: Sr. No Name of component Relationship 1 Torrent Pharmaceuticals Limited Parent 2 AO Torrent Pharma (formerly known as Zao Wholly Owned Subsidiary Torrent Pharma) 3 Torrent Do Brasil Ltda Wholly Owned Subsidiary 4 Torrent Pharma Gmbh Wholly Owned Subsidiary 5 Heumann Pharma Gmbh & Co. Generica KG Wholly Owned Step down Subsidiary 6 Heunet Pharma Gmbh Wholly Owned Step down Subsidiary 7 Torrent Pharma Inc. Wholly Owned Subsidiary 8 Torrent Pharma Philippines Inc. Wholly Owned Subsidiary 9 Laboratories Torrent , S.A. de C.V. Wholly Owned Subsidiary 10 Torrent Australasia Pty Ltd Wholly Owned Subsidiary 11 Torrent Pharma (Thailand) Co., Ltd. Wholly Owned Subsidiary 12 Torrent Pharma (UK) Ltd. Wholly Owned Subsidiary 13 Laboratories Torrent (Malaysia) SDN.BHD. Wholly Owned Subsidiary 14 TPL (Malta) Limited Wholly Owned Subsidiary 15 Torrent Pharma (Malta) Limited Wholly Owned Step down Subsidiary 16 Curatio Inc., Philippines (voluntarily dissolved Wholly Owned Subsidiary with effect from 1 O July 2026) 17 Torrent International Lanka (Pvt) Ltd (Formerly Wholly Owned Subsidiary known as Curatio International Lanka (Pvt) Ltd) 18 Farmaceutica Torrent Colombia SAS Wholly Owned Subsidiary Page 3 of4
Page 15
BS R & Co. LLP 19 20 21 22 23 Limited Review Report (Continued) Torrent Pharmaceuticals Limited Torrent Pharmaceuticals Chile SpA Wholly Owned Subsidiary 000 Unique Pharmaceutical Laboratories Wholly Owned Subsidiary Torrent Pharmawide Trading - FZE (formerly Wholly Owned Subsidiary known as Unique Pharmaceutical Laboratories FZE) Biotech Laboratories (Pty.) Ltd Wholly Owned Step down Subsidiary JBCPL Philippines Inc. Wholly Owned Step down Subsidiary Page 4 of 4
Page 16
TORRENT" TORRENT PHARMACEUTICALS LIMITED PHARMA Registered Office: "Avirat" , Thaltej Shilaj Road, Ahmedabad -380059 , Gujarat, India, Ph.: + 91 79 26599000 Fax: + 91 79 26582100 CIN: L24230GJ1972PLC002126; Website:www .torrentpharma .com; Email: investorservices@torren tpharma .com Statement of Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026 Particulars 1 Revenue from operations (a) Revenue from contracts with customers (b) Other operating income Total revenue from operations 2 Other Income (Refer Note 9) 3 Total income (1+2) 4 Expenses (a) Cost of materials consumed (b) Purchases of stock-in-trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (d) Employee benefits expense (e) Finance costs (f) Depreciation and amortisation expense (g) Other expenses Total expenses 5 Profit before exceptional items and tax (3 - 4) 6 Exceptional items (Refer Note 8) 7 Profit before tax (5 - 6) 8 Tax expense (a) Current tax (b) Deferred tax Total tax expense 9 Net profit for the period (7 - 8) Attributable to : (a) Owners of the company (b) Non-controlling interests 10 Other comprehensive income (A) (i) Items that will not be reclassified subsequently to profit or loss• (ii) Income tax relating to items that will not be reclassified subsequently to profit or loss• (B) (i) Items that will be reclassified subsequently to profit or loss (ii) Income tax relating to items that will be reclassified subsequently to profit or loss Total other comprehensive income Attributab le to: (a) Owners of the company (b) Non-controlling interests 11 Total comprehensive Income (9 + 10) Attributable to : (a) Owners of the company (b) Non-controlling interests 12 Paid-up equity share capital (Face value of Rs. 5 each) 13 Other equity excluding revaluation reserves 14 Earnings per share (Face value of Rs. 5 each) (not annualised) : Basic (in Rs.) Diluted (in Rs.) See accompanying notes to the consolidated financial results *Represents value less than Rs. 0.50 crore. Quarter ended Half Year ended 30-Sep-2026 30-Jun-2026 30-Sep-2025 30-Sep-2026 30-Sep-2025 Unaudited 4896 83 4979 (10) 4969 588 593 43 895 300 609 1194 4222 747 10 737 298 (95) 203 534 534 (12) 3 3 (4) (10) (10) 524 524 190.18 14.05 14.05 Unaudited 4835 86 4921 (12) 4909 609 531 23 893 305 593 1201 4155 754 21 733 254 (87) 167 566 566 (17) 4 119 (27) 79 79 645 645 169.23 14.87 14.87 Unaudited 3246 56 3302 (27) 3275 382 382 36 627 48 204 792 2471 804 13 791 233 (33) 200 591 591 (3) 1 (92) 18 (76) (76) 515 515 169.23 17.45 17.45 Unaudited 9731 169 9900 (22) 9878 1197 1124 66 1788 605 1202 2395 8377 1501 31 1470 552 (182) 370 1100 1100 (29) 7 122 (31) 69 69 1169 1169 190.18 28.92 28.92 Unaudited 6374 106 6480 (64) 6416 778 720 76 1232 104 405 1559 4874 1542 13 1529 434 (44) 390 1139 1139 (12) 3 (94) 25 (78) (78) 1061 1061 169.23 33.64 33.64 (Rs. in crores) Year ended 31-Mar-2026 Audited (Refer Note 6) 13753 227 13980 (94) 13886 1758 1619 11 2671 385 1119 3362 10925 2961 89 2872 844 (110) 734 2138 2163 (25) 0 0 (228) 48 (180) (181) 1 1958 1982 (24) 169.23 8220 63.92 63.92
Page 17
TORRENT" PHAR MA Notes: 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company, in their respective meetings held on October 23, 2026. The statutory auditors have carried out limited review of the above said results. There is no qualification in the auditor's report on this statement of financial results. 2 The consolidated financial results include the financial results of Parent Company and its twenty-two subsidiaries. 3 The Group operat es in a single segment i.e. Generic Formulation Business. 4 Consolidated Balance Sheet (Rs. in crores) Unaudited Audited Particulars As at As at 30-Sep-2026 31-Mar-2026 A ASSETS 1 Non-current assets Property, plant and equipment 4407 4247 Capital work-in -progress 404 457 Investment properties 13 13 Right-of-use assets 659 662 Goodwill 3990 3990 Other intangible assets 23352 24280 Intangible assets under development 200 184 Financial assets Investments 87 83 Loans 2 3 Ot her financial assets 32 44 121 130 Other tax assets (net) 213 227 Deferred tax assets (net) 710 698 Other non-current assets 28 31 Total non-current assets 34097 34919 2 Current assets Inventories 3182 3138 Financial assets Investments 2073 866 Trade receivables 3398 3031 Cash and cash equivalents 891 1117 Bank balances other than cash and cash equivalents 22 48 Loans 5 5 Other financial assets 259 558 6648 5625 Other current assets 687 629 Total current assets 10517 9392 3 Non-current assets held for sale 1 1 TOTAL ASSETS (1+2+3) - 44615 44312 ,6~~ l"'-~.:,_'. 11 TORRENT" ~I t PffARMA -f -y ,C, • • ·. ~ltA1EDP.v,t-:~ -
Page 18
TORRENT'" PHARMA (Rs. in crores) Unaudited Audited Particulars As at As at 30-Sep-2026 31-Mar-2026 B EQUITY AND LIABILITIES 1 Equity Equity share capital 190 169 Other equity 18183 8220 Equity attributable to owners of the company 18373 8389 Non-controlling interests - 9196 Total equity 18373 17585 2 Non-current liabilities Financial liabilities Borrowings 11620 11651 Lease Liabilities 187 190 Other financial liabilities 29 86 11836 11927 Provisions 886 765 Deferred tax liabilities (net) 5517 5670 Other non-current liabilities 19 22 Total non-current liabilities 18258 18384 3 Current liabilities Financial liabilities Borrowings 2254 3147 Lease Liabilities 46 37 Trade payables Total outstanding dues of micro enterprises and small enterprises 130 163 Total outstanding dues of creditors other than micro enterprises 2093 2195 and small enterprises Other financial liabilities 2284 2005 6807 7547 Other current liabilities 134 176 Provisions 518 499 Current tax Liabilities (net) 525 121 Total current liabilities 7984 8343 TOTAL EQUITY AND LIABILITIES {1+2+3) 44615 44312
Page 19
TORRENT" PHARMA 5 Consolidated Statement of Cash Flows Particulars A CASH FLOWS FROM OPERATING ACTIVITIES PROFIT BEFORE TAX Adjustments for : Depreciation and amortisation expense Allowance for expected credit loss (net) Unrealised foreign exchange loss/(gain) (net) Loss on disposal of property, plant & equipment and other intangible assets (Including non-current assets held for sale) (net) Gain on sale of current investments (net) Rent Income Finance costs Interest income Movement in working capital : Trade receivables Loans and other assets Inventories Trade payables Liabilities and provisions CASH GENERATED FROM OPERATIONS Income taxes paid (net of refunds) NET CASH FROM OPERATING ACTIVITIES B CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property, plant & equipme_nt and other intang ible assets (including payment towards capital work-in-progress, intangible assets under development and capital advances) Proceeds from disposal of property, plant & equipment and other intangible assets (Including advance received against non current asset held for sale) (Investment in)/ Redemption of mutual funds (net) Maturity of/ (Investment in) fixed deposits (net) Income from investment properties Interest received NET CASH USED IN INVESTING ACTIVITIES (Rs. in crores) Unaudited Half Year Half Year ended ended 30-Sep-2026 30-Sep-2025 1470 1529 1202 405 8 2 5 (SO) 4 1 (53) (9) (2) - 605 104 (32) (15) 3207 1967 (453) (284) (53) (136) (43) 75 (134) (147) 62 (25) 2586 1450 (134) (412) 2452 1038 (389) (196) 7 2 (1155) 32 303 (67) 1 - so 15 (1183) (214)
Page 20
TORRENT" PHARMA (Rs. in crores) Unaudited Particulars Half Year Half Year ended ended 30-Sep-2026 30-Sep-2025 C CASH FLOWS FROM FINANCING ACTIVITIES Repayment of long-term borrowings (66) (306) Repayment of short term borrowings (net) (954) (153) Repayment of lease liabilities (31) (23) Dividend paid (381) (203) Interest and other borrowing cost paid (73) (141) NET CASH USED IN FINANCING ACTIVITIES (1505) (826) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+ B + C) (236) (2) CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD 1117 573 Effect of exchange rate changes on foreign currency cash and cash 10 so equivalents CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 891 621 6 Consequent to the acquisition of the controlling stake of 48.80% in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma), the Parent Company obtained control over JB Pharma in accordance with Ind AS 110 - Consolidated Financial Statements with effect from January 21, 2026. The results for the year ended March 31, 2026, includes the financial results of JB Pharma and its subsidiaries w.e.f. January 21, 2026. 7 The Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) with the Parent Company was approved by the Hon'ble National Company law Tribunal (NCLT), Ahmedabad Bench, on July 6, 2026. Upon filing the Scheme with Registrar of Companies (ROC), the Scheme became effective on July 8, 2026, with an appointed date of January 21, 2026. Consequently, JB Pharma has been amalgamated with the Parent Company and dissolved without being wound up. On July 20, 2026, the Parent Company allotted 4,19,22,416 fully paid-up equity shares of Rs. 5 each to the eligible shareholders of JB Pharma as on the record date, July 17, 2026, in the share exchange ratio of 51 fully paid up equity shares having face value of Rs. 5 each of the Parent Company for every 100 fully paid up equity shares having face value of Rs. 1 each of JB Pharma. Upon Scheme becoming effective, the non-controlling interest relating to JB Pharma has been derecognised in the consolidated financial results. The amalgamation has no material impact on the consolidated financial results. The financial results do not include the effect of the stamp duty payable in respect of the Scheme of Amalgamation, pending adjudication by the appropriate authority. 8 Exceptional items (i) Includes litigation settlement of Rs. 10 crores for the quarter and half year ended September 30, 2026. (ii) Includes Rs. 2 crores for the quarter ended June 30, 2026 and half year ended September 30, 2026, Rs. 13 crores for the quarter and half year ended September 30, 2025 and Rs. 70 crores for the year ended March 31, 2026, pertaining to regulatory and statutory fees, along with other related costs associated with JB Pharma's acquisition and merger as mentioned in Note 6 and 7 above. (iii) Includes inventory write-off of Rs. 19 crores for the quarter ended June 30, 2026 and half year ended Sep 30, 2026 consequent to fire incident at one of the erstwhile JB Pharma warehouses. No effect has been given to the related insurance claim, which is under assessment. restructuring of JB Pharma's distributi
Page 21
TORRENT" PHARMA 9 Other income mainly includes interest income, net gain on sale of investments, net foreign exchange gain/(loss) and net gain/(loss) on disposal of property, plant & equipment and other intangible assets. 10 Refer Annexure I for disclosure required pursuant to Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). Place : Ahmedabad, Gujarat Date : October 23, 2026 '<!'i~MAc~v,:. ' •• •~ / :;··.,(_ ·,v,r,•~•JT" . -\, For TORRENT PHARMACEUTICALS LIMITED ~ HTA Managing Director DIN: 08174906
Page 22
TORREN1 PHAl-iMA ANNEXURE I : (Rs. in crores except as stated otherwise) Additional Disclosure as per regulation 52(4) of Securities and Exchange Board of India ( Listing Obligations and Disclosure Requirements) Regulations, 2015 Particulars Regulation No. Paid up debt capital Net worth 52(4)(f) Debenture redemption reserve 52(4)(e) Debt equity ratio (in times) 52(4)(a) Debt service coverage ratio (in times) 52(4)(b) Interest service coverage ratio (in times) 52(4)(c) Current ratio (in times) 52(4)(i) Long term debt to working capital (in times) 52(4)0) Bad debts to Account receivables ratio (in times) 52(4)(k) Current liability ratio (in times) 52(4)(1) Total debts to total assets (in times) 52(4)(m) Debtors turnover (in times) (Annualised) 52(4)(n) Inventory turnover (in times) (Annualised) 52(4)(0) Operating margin (in %) 52(4)(p) Net profit margin (in%} 52(4)(q) Ratios have been computed as follows :- (a) Debt equity ratio : Total debt/ Net worth Total debt : Non-current borrowing s + current borrowings Net worth : Equity share capital+ Other equity Quarter ended 30-Sep-2026 30-Jun-2026 30-Sep-2025 11390 11390 643 18373 17848 8449 - - 36 0.76 0.82 0.31 3.89 3.98 2.98 4.53 4.60 17.15 1.32 1.20 1.40 4.28 6.37 0.68 0.02 0.02 O.Ql 0.30 0.31 0.63 0.31 0.33 0.17 5.83 6.09 6.43 6.18 6.14 5.24 33.0% 33.2% 31.7% 10.7% 11.5% 17.9% Half Year ended 30-Sep-2026 30-Sep-2025 11390 643 18373 8449 - 36 0.76 0.31 3.93 3.73 4.56 15.55 1.32 1.40 4.28 0.68 0.02 O.Ql 0.30 0.63 0.31 0.17 6.05 6.29 6.16 5.09 33.1% 31.4% 11.1% 17.6% Year ended 31-Mar-2026 11390 8389 - 1.76 3.26 9.41 1.13 9.26 0.02 0.31 0.33 5.62 4.84 31.7% 15.3% (b) Debt service coverage ratio : (Profit after tax+ Deferred tax+ Depreciation and amortisation+ Interest on debt and lease+ Exceptional items)/ (Interest on debt and lease+ Principal repayments of long term debt including lease payment) (c) Interest service coverage ratio: (Profit after tax + Deferred tax+ Depreciation and amortisation + Interest on debt and lease+ Exceptional items)/ Interest on debt and lease (d) Current Ratio: Total current assets/ Total current liabilities (e) Long term debt to working capital : Non-current borrowings (including current maturities of long-term borrowings)/ Net working capital Net Working capital : Total current assets - Current liabilities Current liabilities: Total current liabilities - current maturities of long-term borrowings (f) Bad debts to Account receivables ratio : Allowances for expected credit loss / Gross trade receivables (g) Current liability ratio : Total current liabilit ies/ Total liabilities (h) Total debts to total assets : Total borrowing/ Total assets Total borrow ing : Non-current borrowings+ current borrowings (i) Debtors turnover: Net sales/ Average trade receivables U) Inventory turnover: Net sales/ Average Inventories (k) Operating margin%: Revenue from operations - (cost of goods sold+ employee benefits+ other expenses)+ (other income - interest income - dividend income)/ Revenue from operations (I) Net profit margin % : Profit after tax/ Revenue from operations
Page 23
Emai l – investorservices@torrentpharma.com Torrent Pharma announces Q2 FY27 results Base India business revenues up 20%; Post-merger integration led transient impact on JB business Ah medabad, 23 rd October 2026: Torrent Pharmaceuticals Limited (“Company”) today announced its financial results for the second quarter of FY27. Key Highlights for Q2 FY27: Revenue at Rs. 4,979 crores, up by 51% YoY Op. EBITDA* at Rs.1,666 crores, up by 54% YoY Op. EBITDA* margin at 33.5%; Gross Margin at 75.4% Net Profit after tax at Rs. 534 crores *Before exceptional items Quarterly Consolidated Financial Summary: Results Q2 FY27 Q2 FY26 YoY % Rs cr % Rs cr % Revenues 4,979 3,302 50.8% Gross profit 3,755 75.4% 2,502 75.8% 50.1% Op EBITDA* 1,666 33.5% 1,083 32.8% 53.8% Exceptional item (10) - (13) - - PAT 534 10.7% 591 17.9% -9.6% R&D spend** 211 4.2% 156 4.7% 35.0% ** R&D spend higher by 0.7% of revenues sequentially in Q2FY27 against Q1FY27 Annexure B TORRENI PHARMA TORRENT PHARMACEUTICALS LIMITED CIN, L24230GJ1972PLC002126 Regd. Office, Avirat, Thaltej Shilaj Road, Ahmedabad - 380059 Phone, +91 79 26599000, Fax, +91 79 26582100, www.torrentpharma.com
Page 24
Email – investorservices@torrentpharma.com Base Business Base revenues at Rs. 3,893 crores were up 18% driven by robust branded performance India: India revenues at Rs. 2,181 crores were up 20% vs IPM growth of 12%, as per the PharmaTrac dataset. Torrent’s Gx Semaglutide recorded Q2 FY27 market share of 32% (oral and injectable combined), as per PharmaTrac Dataset. For H1 FY27, revenues were Rs. 4,338 crores, up by 19%. Brazil: Brazil revenues at Rs. 440 crores were up 38%. Constant currency revenues at R$ 236 million were up by 20%. As per IQVIA, during the quarter, Torrent grew 26% vs market growth of 6%, aided by the performance of top brands and new launches. Torrent has 53 products under ANVISA review. For H1 FY27, revenues were Rs 717 crores, up by 34% (Constant currency revenue: R$ 383 million, up by 13%). United States: US revenues at Rs. 417 crores were up 24%. Constant currency revenues at US$ 44 million were up by 13%. Performance is driven by new launches achieving targeted market share. For H1 FY27, revenues were Rs 835 crores, up by 29% (Constant currency revenue: $88 million up by 17%). Germany: Germany revenues at Rs. 283 crores were down by 7%. Constant currency revenues at EUR 26 million were down by 13%. Growth continued to be impacted by supply disruption at a third-party supplier and loss of certain high volume tenders. For H1 FY27, revenues were Rs 601 crores, down by 2% (Constant currency revenue: EUR 55 million, down by 11%). TORRENI PHARMA TORRENT PHARMACEUTICALS LIMITED CIN, L24230GJ1972PLC002126 Regd. Office, Avirat, Thaltej Shilaj Road, Ahmedabad - 380059 Phone, +91 79 26599000, Fax, +91 79 26582100, www.torrentpharma.com
Page 25
Email – investorservices@torrentpharma.com JB Business Key Performance Metrics: India Rx business (ex of trade generics + contrast media) at Rs. 597 crores grew by 7%. For H1 FY27, revenues were Rs 1,252 crores, up by 10%. International business (US + Emerging Markets + CDMO) revenues at Rs. 406 crores were down by 7%. For H1 FY27, revenues were Rs 874 crores, up by 2%. Following the merger, effective 8 July 2026, integration of the India business, global business network optimisation, and alignment of manufacturing and quality management systems, resulted in a transient impact on revenues during Q2 FY27. Consolidated Revenue Summary Region Q2 FY27 (Rs. crore) Q2 Growth (%) Base JB Total Base Reported Business Business India 2,181 680 2,861 20% 57% International 1,585 406 1,991 18% 48% Others 127 - 127 -9% -9% Total 3,893 1,086 4,979 18% 51% Half Yearly Consolidated Financial Summary Results H1 FY27 H1 FY26 YoY % Rs cr % Rs cr % Revenues 9,900 6,480 52.8% Gross profit 7,513 75.9% 4,906 75.7% 53.1% Op EBITDA* 3,330 33.6% 2,115 32.6% 57.4% Exceptional item (31) - (13) - - PAT 1,100 11.1% 1,139 17.6% -3.4% R&D spend 383 3.9% 313 4.8% 22.4% TORRENI PHARMA TORRENT PHARMACEUTICALS LIMITED CIN, L24230GJ1972PLC002126 Regd. Office, Avirat, Thaltej Shilaj Road, Ahmedabad - 380059 Phone, +91 79 26599000, Fax, +91 79 26582100, www.torrentpharma.com
Page 26
Email – investorservices@torrentpharma.com About Torrent Pharmaceuticals: Torrent Pharma is the flagship Company of the Torrent Group, with group revenues of approximately Rs 50,000 crores. It is ranked 5 th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), Pain Management and Derma. It is a specialty-focused company with ~75% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil and Germany. Torrent Pharma has 16 manufacturing facilities, of which 8 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 900+ scientists. TORRENI PHARMA TORRENT PHARMACEUTICALS LIMITED CIN , L24230GJ1972PLC002126 Regd. Office , Avirat, Thaltej Shilaj Road, Ahmedabad - 380059 Phone , +91 79 26599000 , Fax, +91 79 26582100 , www.torrentpharma.com